Global expansion AcceleDev has recently expanded its manufacturing footprint with a new facility in Cranbury, New Jersey and already operates facilities in the US and China, signaling capacity growth and multi-region supply capabilities that can support partner API programs requiring regional production and risk diversification.

Small molecule focus As a private US-based CDMO specializing in small molecule process chemistry from preclinical to commercialization, AcceleDev offers end-to-end services including process design, R&D, analytics, pilot scale-up and commercial production, presenting a one-stop option for pharma partners seeking streamlined development and supply continuity.

Clinical to commercial With a track record of tens of thousands of projects and a customer-first approach, AcceleDev emphasizes fast turnaround times and scalable synthesis models, appealing to partners aiming to accelerate timelines from preclinical studies through commercial launch.

Industry engagement Active participation in major pharma events (CPHI Barcelona, ChemOutsourcing, Pharma ChemOutsourcing) and leadership by PhD chemists enhances visibility among potential collaborators and suggests opportunities to connect with decision-makers at large pharmaceutical programs seeking CRO/CDMO partners.

Competitive positioning Despite being a smaller private CDMO, AcceleDev’s global footprint, rigorous process chemistry expertise, and integrated supply chain services position it as a compelling alternative for mid-to-large pharma companies seeking flexible, high-quality small-molecule manufacturing partners with regional production capabilities.